(Total Views: 455)
Posted On: 05/19/2024 8:23:29 AM
Post# of 148870
sorry ohm, let me make a better reply.
So, at the time, Cyrus had been demoted from President to now VP but he wanted this MD Anderson trial to begin already.
The BOD also wanted the same, but their first priority was to the FDA and the FDA made the Company jump through hoops to get the hold lifted.
They even made them chase a very narrow HIV population to get the hold lifted.
First off, you're bringing in mTNBC where this is on mCRC. and I agree with you that this is perfectly fine b/c mTNBC is also the hardest of all the breast cancers to treat and also has both MSS and MSI type tumors which is the same in mCRC. So given the assumption that leronlimab was able to outperform Keytruda in the prior trial against mTNBC in these difficult cancers, so it would also outperform Keytruda in mCRC in a bonafide phase II clinical trial, regardless of how it performed against leronlimab in a mCRC murine study.
Secondly, you're saying that Merck scrapped it. But biloxi said our BOD scrapped it. Could you be implying some sort of blackmail? Merck tells our BOD to scrap it or else. Or was it a bribe? Scrap it and this is how we will return the favor? Certainly, the BOD decided in compliance and went against the wishes of Cyrus, but he had no say as he was only VP.
I believe our BOD made the decision they did because their 1st allegiance was to the FDA and they did not want to overstep or make any mistake whatsoever, but there could have been ulterior motives at play. So, thank you.
So, at the time, Cyrus had been demoted from President to now VP but he wanted this MD Anderson trial to begin already.
The BOD also wanted the same, but their first priority was to the FDA and the FDA made the Company jump through hoops to get the hold lifted.
They even made them chase a very narrow HIV population to get the hold lifted.
First off, you're bringing in mTNBC where this is on mCRC. and I agree with you that this is perfectly fine b/c mTNBC is also the hardest of all the breast cancers to treat and also has both MSS and MSI type tumors which is the same in mCRC. So given the assumption that leronlimab was able to outperform Keytruda in the prior trial against mTNBC in these difficult cancers, so it would also outperform Keytruda in mCRC in a bonafide phase II clinical trial, regardless of how it performed against leronlimab in a mCRC murine study.
Secondly, you're saying that Merck scrapped it. But biloxi said our BOD scrapped it. Could you be implying some sort of blackmail? Merck tells our BOD to scrap it or else. Or was it a bribe? Scrap it and this is how we will return the favor? Certainly, the BOD decided in compliance and went against the wishes of Cyrus, but he had no say as he was only VP.
I believe our BOD made the decision they did because their 1st allegiance was to the FDA and they did not want to overstep or make any mistake whatsoever, but there could have been ulterior motives at play. So, thank you.
(4)
(0)Scroll down for more posts ▼
